On the Progression From Early-to Late-Stage Melanoma: A Potential Sequence of Molecular Events Using Data From Droplet Digital PCR and Array Comparative Genomic Hybridization, A Pilot Study.
Jason R McFadden, Arkar Htoo, Advaita S Chaudhari, Mirjana Stevanovic, Gregory J Tsongalis, Edward G Hughes, Aravindhan Sriharan
{"title":"On the Progression From Early-to Late-Stage Melanoma: A Potential Sequence of Molecular Events Using Data From Droplet Digital PCR and Array Comparative Genomic Hybridization, A Pilot Study.","authors":"Jason R McFadden, Arkar Htoo, Advaita S Chaudhari, Mirjana Stevanovic, Gregory J Tsongalis, Edward G Hughes, Aravindhan Sriharan","doi":"10.1097/DAD.0000000000003350","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Melanoma progression is generally associated with a stepwise increase in genomic complexity. Although the copy number variations (CNVs) known to occur in melanoma are well characterized, the order in which they accumulate during melanomagenesis remains incompletely understood. To explore this, we used droplet digital polymerase chain reaction to calculate absolute copy numbers of RREB1 and CDKN2A , the most commonly amplified and deleted genes in melanoma, in 51 formalin-fixed, paraffin-embedded melanomas. Each sample also underwent chromosomal microarray analysis to determine its CNV burden, which we graded according to the number of the following melanoma-associated CNVs present: RREB1 gain, CDKN2A loss, MYC gain, and MYB loss. In this pilot study, increasing CNV burden was associated with a gradual increase in average RREB1 copy number: from 2.00 in CNV-negative melanomas to 2.68 in melanomas with isolated RREB1 gain; 2.75 in melanomas with RREB1 gain and CDKN2A loss; 2.93 in melanomas with RREB1 gain and MYC gain; and 3.23 in melanomas with RREB1 gain, CDKN2A loss, and MYC gain ( F = 10.43, P < 0.001). A parallel trend was observed for average CDKN2A copy number, which decreased progressively with increasing CNV burden: from 2.02 in CNV-negative melanomas to 1.33 in melanomas with isolated CDKN2A loss; 1.15 in melanomas with CDKN2A loss and MYC gain; and 0.53 in melanomas with CDKN2A loss and MYB loss ( F = 12.01, P < 0.001). These findings support a potential model of stepwise CNV accumulation in melanoma: early RREB1 gain and/or CDKN2A loss, followed by MYC gain, and ultimately MYB loss.</p>","PeriodicalId":50967,"journal":{"name":"American Journal of Dermatopathology","volume":" ","pages":"853-859"},"PeriodicalIF":0.8000,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Dermatopathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/DAD.0000000000003350","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/16 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Abstract: Melanoma progression is generally associated with a stepwise increase in genomic complexity. Although the copy number variations (CNVs) known to occur in melanoma are well characterized, the order in which they accumulate during melanomagenesis remains incompletely understood. To explore this, we used droplet digital polymerase chain reaction to calculate absolute copy numbers of RREB1 and CDKN2A , the most commonly amplified and deleted genes in melanoma, in 51 formalin-fixed, paraffin-embedded melanomas. Each sample also underwent chromosomal microarray analysis to determine its CNV burden, which we graded according to the number of the following melanoma-associated CNVs present: RREB1 gain, CDKN2A loss, MYC gain, and MYB loss. In this pilot study, increasing CNV burden was associated with a gradual increase in average RREB1 copy number: from 2.00 in CNV-negative melanomas to 2.68 in melanomas with isolated RREB1 gain; 2.75 in melanomas with RREB1 gain and CDKN2A loss; 2.93 in melanomas with RREB1 gain and MYC gain; and 3.23 in melanomas with RREB1 gain, CDKN2A loss, and MYC gain ( F = 10.43, P < 0.001). A parallel trend was observed for average CDKN2A copy number, which decreased progressively with increasing CNV burden: from 2.02 in CNV-negative melanomas to 1.33 in melanomas with isolated CDKN2A loss; 1.15 in melanomas with CDKN2A loss and MYC gain; and 0.53 in melanomas with CDKN2A loss and MYB loss ( F = 12.01, P < 0.001). These findings support a potential model of stepwise CNV accumulation in melanoma: early RREB1 gain and/or CDKN2A loss, followed by MYC gain, and ultimately MYB loss.
期刊介绍:
The American Journal of Dermatopathology offers outstanding coverage of the latest diagnostic approaches and laboratory techniques, as well as insights into contemporary social, legal, and ethical concerns. Each issue features review articles on clinical, technical, and basic science advances and illuminating, detailed case reports.
With the The American Journal of Dermatopathology you''ll be able to:
-Incorporate step-by-step coverage of new or difficult-to-diagnose conditions from their earliest histopathologic signs to confirmatory immunohistochemical and molecular studies.
-Apply the latest basic science findings and clinical approaches to your work right away.
-Tap into the skills and expertise of your peers and colleagues the world over peer-reviewed original articles, "Extraordinary cases reports", coverage of practical guidelines, and graphic presentations.
-Expand your horizons through the Journal''s idea-generating forum for debating controversial issues and learning from preeminent researchers and clinicians